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The Obesity and Fatty Liver Are Reduced by Plant-
Derived Pediococcus pentosaceus LP28 in High Fat Diet-
Induced Obese Mice
Xingrong Zhao, Fumiko Higashikawa, Masafumi Noda, Yusuke Kawamura, Yasuyuki Matoba, Takanori
Kumagai, Masanori Sugiyama*
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Abstract
We evaluated the effect of an oral administration of a plant-derived lactic acid bacterium, Pediococcus pentosaceus LP28
(LP28), on metabolic syndrome by using high fat diet-induced obese mice. The obese mice were divided into 2 groups and
fed either a high fat or regular diet for 8 weeks. Each group was further divided into 3 groups, which took LP28, another
plant-derived Lactobacillus plantarum SN13T (SN13T) or no lactic acid bacteria (LAB). The lean control mice were fed a
regular diet without inducing obesity prior to the experiment. LP28 reduced body weight gain and liver lipid contents
(triglyceride and cholesterol), in mice fed a high fat diet for 8 weeks (40%, 54%, and 70% less than those of the control
group without LAB, and P= 0.018, P,0.001, and P= 0.021, respectively), whereas SN13T and the heat treated LP28 at 121uC
for 15 min were ineffective. Abdominal visceral fat in the high fat diet mice fed with LP28 was also lower than that without
LAB by 44%, although it was not significant but borderline (P= 0.076). The sizes of the adipocytes and the lipid droplets in
the livers were obviously decreased. A real-time PCR analyses showed that lipid metabolism-related genes, such as CD36
(P= 0.013), SCD1 encoding stearoyl-CoA desaturase 1 (not significant but borderline, P= 0.066), and PPARc encoding
peroxisome proliferator-activated receptor gamma (P= 0.039), were down-regulated by taking LP28 continuously, when
compared with those of the control group. In conclusion, LP28 may be a useful LAB strain for the prevention and reduction
of the metabolic syndrome.
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Introduction
Metabolic syndrome is a cluster of abnormalities such as obesity,
hypertension, dyslipidemia, and/or diabetes, which increases the
risk of developing cardiovascular disease. The prevalence of this
syndrome has been increasing in conjunction with industrial
development, particularly in advanced nations. Of these risk
factors, obesity, especially visceral adipose tissue accumulation, is
considered as the major cause of cardiovascular disease [1]. The
combination of dietary restrictions and physical exercise is effective
for combating obesity and other metabolic disorders; however, the
task is not easily achieved by most obese individuals.
Lactic acid bacteria (LAB) used for various fermented foods have
therapeutic effects on human health, and their consumption has
resulted in improvements of diverse gastrointestinal disorders,
positive immunomodulation, and prevention of cancer [2–4]. LAB
are major representatives of probiotics, which have been defined by
the World Health Organization (WHO) as live microorganisms
that, when administered in adequate amounts, confer a health
benefit on the host. LAB is the generic name given to non-spore-
forming Gram-positive bacteria that produce a large amount of
lactic acid by the fermentation of various sugars and carbohydrates
and can be roughly classified into two groups according to the
difference in their living environments. One is derived from
animals, and the other, from plants. Animal-derived LAB are
generally used for the production of yogurt and cheese, and plant-
derived bacteria are used in fermented foods, such as pickles, soy
sauce, and grass silage. Previous studies suggest that plant-derived
LAB are superior to animal-derived ones with regard to acid
tolerance, immune-stimulating activity, and/or intestinal regulation
[5–7]. Although various probiotic properties of LAB have been
found until now, sufficiently potent probiotics to combat obesity
have not been found yet. Some potent probiotics to prevent obesity
might exist, as indicated by several reports on the serum lipid-
lowering properties of lactobacilli [8–10]. Our previous clinical
study suggests that a plant-derived strain, Lactobacillus plantarum
SN13T (SN13T), isolated in our laboratory, is beneficial for
improving liver function, as shown by measurements of serum
aspartate aminotransferase (AST), alanine aminotransferase (ALT),
and gamma glutamyl transpeptidase (c-GTP), in addition to
remarkable improvement of constipation [7]. We speculate that
SN13T may have improved liver function in the clinical study by
somehow reducing hepatic lipid contents in the study subjects with
non-alcoholic or alcoholic fatty liver. In the present study, we,
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therefore, focused on contributions of the plant-derived LAB
consumption to obesity assuming that it would change the lipid
metabolism. Several LAB strains, including newly isolated Pedio-
coccus pentosaceus LP28 (LP28) from the longan fruit, Lactobacillus
plantarum, Enterococcus mundtii, and Lactobacillus delbrueckii subsp.
bulgaricus, were preliminarily screened to determine whether or
not they influence body weight in obesity-induced mice. We then
proceeded using LP28 and SN13T and investigated their effects on
body weight gain, visceral fat accumulation, plasma lipids, hepatic
lipid contents, and the expression of some lipid metabolism-related
genes in a high fat diet (HFD)-induced mouse model.
Methods
Ethics statement
Animal experiments were conducted in accordance with the
‘‘Guidelines for the Care and Use of Laboratory Animals’’
established by Hiroshima University, and all experimental
procedures involving animals were approved by the Committee
of Research Facilities for Laboratory Animal Science of Hiroshima
University (Permit Number: A07-65).
Isolation and identification of LP28
LP28 was newly isolated from longan fruit (Euphoria longana) by
the method as described previously [11], identified by determining
the entire 16S rDNA sequence by using previously reported
methods [12–14], and compared with that of typical LAB
obtained from the DNA Data Bank of Japan (DDBJ) Website [15].
Experimental diets and LAB supplementation
The compositions of HFD (#D12492, Research Diets, Inc.,
New Brunswick, NJ) and regular diet (RD), which is a product
named as ‘‘MF’’ manufactured by Oriental Yeast Co., Ltd., Japan,
were shown in Table 1. Each cell mass of LP28 and SN13T,
cultured in de Man-Rogosa-Sharpe (MRS) broth (Merck KGaA,
Darmstadt, Germany) was collected by centrifugation and washed
twice with phosphate-buffered saline (pH 7.4). The washed cell
mass was lyophilized to make its powder and kept at 280uC until
use. The lyophilized LAB was mixed with either RD or HFD at
final concentrations of 1.256109 cfu/g. Diets of all groups were
exchanged to maintain freshness every 7 d.
Experimental animals
Male C57BL/6Jcl (SPF) mice, 6 to 7 weeks of age, were
purchased from CLEA Japan, Inc. Mice were divided into seven
groups of five mice each and were housed in plastic cages for each
group under 40–60% humidity, controlled temperature (20–
26uC), and 12 h light/dark cycles. Mice had free access to each
diet and water. Six of the seven groups were fed HFD for 6 weeks
to induce obesity before the oral administration of LAB. The
remaining one group was continued to feed a RD as a lean control
(RD/RD) mice without the induction of obesity. At the start of 8
week experimental period, each group was assigned to a HFD or
RD, with or without LAB (Table 2). LAB were administered to
mice for 8 weeks, and the food intakes were monitored by
weighing the remaining diet from each cage when changing it.
Body weight change of each mouse was recorded weekly, and
blood samples were obtained from the mouse tail vein every 2
weeks for plasma lipid measurement. Food efficiencies were
calculated as [body weight gain in 8 weeks] per [food intake in 8
weeks] [16]. After the experimental period, mice were killed by
diethyl ether anesthesia, and followed by the isolation of livers and
total visceral adipose tissues, such as mesenteric, epididymal, and
retroperitoneal adipose tissue. We added two groups of two mice
each (aged 6 to 7 weeks) to the seven groups (RD/RD, HFD/
HFD-C, HFD/HFD-LP28, HFD/HFD-SN13T, HFD/RD-C,
HFD/RD-LP28, and HFD/RD-SN13T), to check whether
obesity was induced by feeding HFD for 6 weeks, since the mice
in seven groups could not be used to determine the amount of total
visceral adipose tissue, liver weight, and liver lipid contents at this
point due to extirpation of the liver and adipose tissues. The
additional two groups were also housed and fed either RD or HFD
for 6 weeks at the same conditions as either RD/RD or other six
experimental groups.
Plasma and liver lipid contents
The isolated livers were weighed after rinsed with phosphate-
buffered saline and blotted dry with filter paper. Each liver was
homogenized in 20 volumes of an extraction solution (chloroform:
methanol = 2:1; v/v) and agitated for 60 min at room tempera-
ture. The triglyceride and cholesterol levels in plasma and liver
extraction were measured using the Triglyceride E-test Wako and
Cholesterol E-test Wako (Wako Pure Chemical Industries, Osaka,
Japan) according to the manufacturer’s instructions.
Histological analysis
Liver and visceral adipose tissue sections were 10% formalin-
fixed, paraffin-embedded, and stained with hematoxylin-eosin
(HE). Adipocyte numbers were counted in 4 different spots per
mouse.
Gene expressions
Quantitative real-time PCR analyses were performed for lipid
metabolism-related gene expression in the liver. Briefly, total RNA
was isolated from each liver using the SV Total RNA Isolation
System (Promega, Madison, WI). The purity and integrity of RNA
preparations were checked spectroscopically and by agarose gel
electrophoresis. The total RNA was converted to cDNA using the
RevertAid H Minus First-Strand TaKaRa RNA PCR Kit (Takara
Bio Inc.) according to the manufacturer’s instructions. Quantita-
tive real-time PCR was performed with the iQ SYBR Green
Supermix (TOYOBO Co. Osaka, Japan) and DNA Engine
Opticon (Bio-Rad Laboratories, Hercules, CA). Primer sets for
real-time PCR for glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
CD36, Stearoyl-CoA desaturase-1 (SCD1), and peroxisome proliferator-
activated receptor gamma (PPARc) were obtained from Takara
(GAPDH: MA050371, CD36: MA000930, SCD1: MA027073,
PPARc: MA029809).
Statistical analysis
Statistical analyses were performed using SPSS (version 17.0:
Statistical Package for the Social Sciences, SPSS Japan, Inc.). Due to
non-normal distributions, liver weight, liver triglyceride, liver
cholesterol, CD36, SCD1, and PPARc were logarithmic transformed
Table 1. Composition of high fat diet (HFD) and regular diet
(RD).
HFD RD
Protein (% of energy) 20.0 26.2
Carbohydrate (% of energy) 20.0 60.4
Fat (% of energy) 60.0 13.3
Energy (kJ/g) 21.9 15.1
doi:10.1371/journal.pone.0030696.t001
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before the analysis. One-way ANOVA with Tukey’s post hoc test
was applied for all variables except for visceral fat, liver weight, liver
triglyceride, and CD36 in each diet group. The four variables were
examined by Welch’s ANOVA with the Tamhane post hoc test
within each diet group, due to unequal variances. Dunnett’s tests
were done to compare each treatment group with RD/RD. The
two-way ANOVA was also applied to evaluate the effects of diet,
treatment, and interaction between the diet and treatment. To
check the obese state at the starting point of experimental period, all
mice available were used for the analyses; in short, 34 mice (three
HFD/HFD groups, three HFD/RD groups, and additional two
mice) fed HFD and 7 mice (RD/RD mice and additional two
mice) fed RD were used for the analyses of body weight, plasma
cholesterol, and triglyceride levels; and each of two additional mice
fed HFD or RD were used for the amount of adipose tissue, liver
cholesterol, and liver triglyceride contents. All data are presented as
mean values with their standard errors. P,0.05 were considered
significant.
Results
Obese state at the starting point of experimental period
Body weight after the 6 weeks obesity induction period was
higher in the obese mice (HFD/HFD-C, HFD/HFD-LP28, HFD/
HFD-SN13T, HFD/RD-C, HFD/RD-LP28, and HFD/
RD-SN13T; 32.060.7 g) than that in RD/RD (27.160.6 g;
P= 0.001, student t test). The plasma cholesterol level in the obese
mice (1257644 mg/L) were significantly higher than that in RD/
RD (804651 mg/L, P,0.001, student t test), whereas the plasma
triglyceride levels did not alter in obese mice (1873664 mg/L in
obese mice and 1880661 mg/L in RD/RD). The amount of
abdominal adipose tissue, liver cholesterol, and liver triglyceride
contents were 2.8660.60 g, 6.662.2 mg/liver, and 27.962.9 mg/
liver in mice fed HFD or 0.5760.01 g, 5.160.8 mg/liver, and
23.365.1 mg/liver in mice fed RD, respectively, after the obesity
induction period for 6 weeks.
Anti-obesity effect of LP28
The body weight gain of HFD/HFD-LP28 was reduced by
40.7% during 8 weeks when compared to HFD/HFD-C
(P= 0.018), whereas that of HFD/HFD-SN13T did not differ
from HFD/HFD-C (Table 3). The reduction of weight gain in
HFD/HFD-LP28 was started at week 2 (data not shown. Student t
test, P= 0.032 versus HFD/HFD-C at the time point). The HFD/
RD groups (HFD/RD-C, HFD/RD-LP28, and HFD/RD-
SN13T) in which obesity had been induced by a HFD, followed
by changing to a RD at the starting point of LAB administration,
quickly returned to a normal body weight with reduced plasma
cholesterol level (Table 3). Contrary to the result from the HFD/
HFD groups, the body weight gain of HFD/RD-LP28 was not
significantly lower than HFD/RD-C or HFD/RD-SN13T. There
were no significant differences in the amounts of food intake
and energy intake among the same diet groups, which had been
recorded to determine whether or not their appetites had been
depressed by supplement of LAB (Table 3). Food efficiency was
significantly lower in HFD/HFD-LP28 than HFD/HFD-C and
HFD/HFD-SN13T (P= 0.023 and P= 0.011, respectively). Plas-
ma cholesterol levels in both the HFD/HFD and HFD/RD
groups were not influenced by the consumption of LP28 and
SN13T. The plasma triglyceride levels were unchanged by diet or
LAB (Table 3). Two-way ANOVA showed a significant effect to
visceral fat amounts in the diet and interaction between the diet
and treatment. According to the analysis within the same diet
group, the visceral fat in HFD/HFD-LP28 tended to be reduced
when compared with that in HFD/HFD-C (P= 0.076). In the
HFD/HFD-C group, HFD for additional 8 weeks induced 10.8 g
of body weight gain and approximately 1.2 g of visceral fat gain,
when compared with the starting point of experimental period
(visceral fat amount: 2.86 g). However, although the body weight
gain was 6.4 g by the LP28 treatment, the visceral fat was
constant. In contrast, no quantitative difference of visceral fat
among HFD/RD groups was observed. Judging from these
observations, LP28-administrative effect may be different depend-
ing on the nutritional environment. The HFD/RD groups (HFD/
RD-C, HFD/RD-LP28, and HFD/RD-SN13T) lost most of the
visceral fat accumulation, which was formed during 6 week period
of a high fat load prior to the experimental period (Table 3).
Judging from the changes in adipocyte number per spot, the
adipocyte size, which had become enlarged in HFD/HFD-C, was
restored in HFD/HFD-LP28 but not in HFD/HFD-SN13T
(Figure 1).
Reduction of fatty liver by LP28
Triglyceride contents in the livers from HFD/HFD-C and
HFD/HFD-SN13T showed a 3.7- (P,0.001) and 5.1-fold
(P,0.001) higher than that from RD/RD, respectively, being in
Table 2. Experimental design.
Groups
Diet type during the obesity
induction period (6 weeks)
Diet type during the
experimental period (8
weeks)
LAB supplementations during the
experimental period (8 weeks)
Lean mice RD/RD RD RD -
Obese mice fed a HFD HFD/HFD-C HFD HFD -
HFD/HFD-LP28 HFD HFD LP28
HFD/HFD-SN13T HFD HFD SN13T
Obese mice fed a RD HFD/RD-C HFD RD -
HFD/RD-LP28 HFD RD LP28
HFD/RD-SN13T HFD RD SN13T
HFD, high fat diet; RD, regular diet.
RD/RD, lean control group; HFD/HFD-C, obese control group fed a HFD; HFD/HFD-LP28, obese group fed the LP28-supplemented HFD; HFD/HFD-SN13T, obese group
fed the SN13T-supplemented HFD.
HFD/RD-C, obese control group fed a RD; HFD/RD-LP28, obese group fed the LP28-supplemented RD; HFD/RD-SN13T, obese group fed the SN13T-supplemented RD.
doi:10.1371/journal.pone.0030696.t002
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a condition referred to as ‘‘fatty liver’’ (Table 3). Although liver
triglyceride content in HFD/HFD-LP28 was still higher than that
of RD/RD (1.7-fold, P= 0.007), it was significantly lower when
compared with HFD/HFD-C and HFD/HFD-SN13T (P,0.001
and P,0.001, respectively). Mice switched from the HFD to the
RD for 8 weeks had liver triglyceride levels which were not
different from the RD/RD. Hepatic cholesterol content in HFD/
HFD-LP28 was also significantly less than those in HFD/HFD-C
and HFD/HFD-SN13T (P= 0.021 and P= 0.012, respectively;
Table 3). Moreover, the micrograph of the liver tissue sections
shows that many massive lipid droplets were present in the HFD/
HFD-C hepatic tissues, and had obviously shrunk in the HFD/
HFD-LP28 liver, whereas SN13T did not affect the size of the
lipid droplets in hepatic cells (Figure 2), in accordance with the
results of the liver triglyceride content.
Gene expression signature in hepatic cells in response to
LP28
The real-time PCR analysis for liver tissues isolated from HFD/
HFD-C and HFD/HFD-LP28 groups showed that the CD36,
SCD1, and PPARc expressions in HFD/HFD-LP28 were down-
regulated when compared with those in HFD/HFD-C, as shown
in Table 4. The CD36 expression was highly induced in HFD/
HFD-C in contrast to the RD/RD group (P,0.001); however, the
induced expression of CD36 in HFD/HFD-C was significantly
suppressed in HFD/HFD-LP28 (P= 0.013) but not in HFD/
HFD-SN13T. SCD1 expression in HFD/HFD-LP28 was lower
than that of HFD/HFD-C (P= 0.066), and PPARc expression was
reduced in HFD/HFD-LP28 when compared with HFD/HFD-C
and HFD/HFD-SN13T (P= 0.039 and P= 0.044, respectively).
Although two-way ANOVA showed significant treatment effects
and no interaction effect between diet and treatment on CD36 and
PPARc expressions, no significant reductions in the CD36 and
PPARc expressions were observed in HFD/RD-LP28 group when
compared with HFD/RD-C group.
Discussion
We have previously shown that SN13T had significant capacity
to enhance immune responses and to improve gastrointestinal
Figure 1. Effect of LAB supplementations on adipocyte size in obese mice. A, RD/RD; B, HFD/HFD-C; C, HFD/HFD-LP28; D, HFD/HFD-SN13T.
Magnification,6400. E, mean values of cell number per spot with their SE for 4 distinct areas per mouse. *P,0.05, ***P,0.005.
doi:10.1371/journal.pone.0030696.g001
Figure 2. Effect of LAB supplementations on hepatic lipid contents in obese mice. A, RD/RD; B, HFD/HFD-C; C, HFD/HFD-LP28; D, HFD/
HFD-SN13T. Magnification,6400.
doi:10.1371/journal.pone.0030696.g002
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conditions and liver function [6,7]. In this study, however, a newly
isolated LAB, Pediococcus pentosaceus LP28, was demonstrated to be
a potent anti-obesity probiotic, in contrast to the SN13T. We
observed that LP28 killed by autoclaving at 121uC for 15 min is
ineffective to reduce the obesity (10.360.6 g and 8.960.4 g weight
gains in 8 weeks in control and heat-killed LP28 groups,
respectively. P.0.05).
To evaluate the anti-obesity effects of the LAB strains, we
arranged three sets of conditions for the mice. In one, we used
normal mice (RD/RD) fed a typical diet for the entire
experimental period; in the second, obese mice were fed a HFD
(HFD/HFD-C, HFD/HFD-LP28, and HFD/HFD-SN13T); and,
in the third, mice were fed a HFD for 6 weeks of obesity induction
period and followed by feeding RD for 8 weeks during
experimental period (HFD/RD-C, HFD/RD-LP28, and HFD/
RD-SN13T). The results indicate that 8 week intake of a proper
nutrient diet was sufficient to restore the body weight as well as the
visceral fat and hepatic lipid storage.
The CD36 expression in liver was also recovered in the HFD/
RD groups (no significant difference is observed from RD/RD),
however, SCD1 expression levels were even increased in HFD/
RD-C and HFD/RD-LP28 (P= 0.029 and P= 0.015 vs. RD/RD
by Dunnett’s test, respectively). This indicates that the nutritionally
balanced food easily and quickly reduces fat accumulation
regardless of the expression levels of SCD1. LP28 intake
remarkably suppressed body weight gain caused by an extraordi-
narily fatty diet. The extent of weight gain suppression was 14.1%
of initial body weight within only 8 weeks with LP28 supplemen-
tation, which is more than the range of 5% to 10% of weight
reduction recommended by the U.S. National Heart, Lung, and
Blood Institute, the WHO, and the Canadian Obesity Guidelines
in order to reduce health risk of chronic disease [17–19].
Moreover, LP28 did not abnormally reduce the body weight of
the HFD/RD groups, indicating that LP28 is effective only when
nutrients are in excess. In this study, each mouse was administered
approximately 36109 cfu/day of LAB, which is equivalent to
4.561011 cfu/day in human, when calculated by using the body
surface area normalization method [20]. Although the currently
used dosages of probiotics are 108,1011 cfu/day, the optimum
dosage required for probiotics have not reached to a consensus
[21]. Clinical study should be required to determine the effective
dosage of LP28 in human. Body weight gain reduction by LP28
was accompanied by diverse changes, which included decrements
of visceral fat amount, adipocyte size, lipid droplet size in liver,
hepatic triglycerides contents, hepatic cholesterol contents, and
hepatic gene expressions. However, LP28 had no effect on blood
lipids, triglycerides and cholesterol. In addition, we evaluated
plasma adiponectin concentrations, but no significant change was
observed. It is possible that plant-derived LAB administered orally
might adsorb dietary cholesterol or other lipids, which might then
be excreted with feces. However, the cholesterol and fatty acid
contents in feces were not increased in the HFD/HFD-LP28
group (data not shown).
The ingredient in RD may not match that in HFD. In this
study, we performed the Dunnett’s test to compare each of three
HFD/HFD and three HFD/RD groups to lean control mice
(RD/RD). Although this analysis is the comparison between
different diet types, an aim of these comparisons is to know that
whether the results from these experimental groups are close to
that from RD/RD. A leading conclusions, which the intake of
LP28 reduces the body weight gain and liver lipid contents, are
obtained from the comparisons among the same diet group, such
as among HFD/HFD-C, HFD/HFD-LP28, and HFD/HFD-
SN13T, by the Tukey’s test or the Tamhane test. Therefore, even
if the ingredients in HFD are different from that in RD, it is clear
that the intake of LP28 has these anti-obesity effects.
To elucidate the mechanism that combats obesity by LP28, we
screened altered expressions of genes participating in lipid
metabolism and biosynthesis. The expression level of CD36,
which functions as a transporter for fatty acid and oxidized low-
density lipoproteins [22,23], is very low in normal liver tissue.
CD36 was drastically enhanced in a HFD-induced fatty liver and
nonalcoholic fatty liver in humans, and these elevated levels of
CD36 expression correlated with hepatic fat contents [24,25].
Conversely, forced expression of hepatic CD36 without a HFD
caused hepatic steatosis [24]. It has also been reported that the
development of fatty liver was prevented in CD36 null mice [26].
The result as shown in Table 4 is agreeable with those from
previous reports. Hepatic CD36 expression in obese mice was
considerably enhanced and paralleled by increased hepatic fat
content. Upon LP28 administration, CD36 expression and fat
storage in the liver are concurrently reduced. These observations
suggest that CD36 is associated with the prevention of hepatic
steatosis achieved by LP28 intake.
A research group showed that SCD1 is predominantly
expressed in liver and converts saturated fatty acids to monoun-
Table 4. CD36, SCD1, and PPARc mRNA expression levels in the liver after the oral administration of LAB for 8 weeks, which was
examined by using the real-time PCR1, 2.
Lean
mice
Obese mice fed a HFD during the
experimental period
Obese mice fed a RD during the
experimental period Two-way ANOVA (P)
Variables RD/RD
HFD/
HFD-C
HFD/
HFD-LP28
HFD/
HFD-SN13T
HFD/
RD-C
HFD/
RD-LP28
HFD/
RD-SN13T Diet Treatment Interaction
CD36 0.760.2 34.3610.8*** 5.561.91 9.063.3*** 3.861.3 1.660.4 4.461.5 ,0.001 0.028 NS3
SCD1 2.960.8 6.462.2 2.260.4 4.662.0 9.262.2* 9.462.4* 6.061.8 0.002 NS NS
PPARc 2.860.8 4.661.1 1.560.3{ 4.561.4 4.361.0 3.360.7 4.561.1 NS 0.019 NS
1Data are mean 6 SE, n = 5.
2The data are expressed relative to GAPDH mRNA.
3NS, Not significant.
*P,0.05.
***P,0.005 vs. RD/RD.
1P,0.05 vs. HFD/HFD-C.
{P,0.05 vs. HFD/HFD-C and HFD/HFD-SN13T.
doi:10.1371/journal.pone.0030696.t004
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saturated fatty acids, which are major substrates for the synthesis
of triglycerides, cholesterol esters, and other lipids [27]. SCD1-
deficient mice have shown resistance to diet-induced obesity,
increased insulin sensitivity, reduced hepatic lipid accumulation,
and/or even increased energy expenditure [28–30]. Thus, SCD1
may be a key gene to treat obesity. Our results suggest that the
resistance to weight gain and hepatic fat accumulation as a
consequence of LP28 consumption against a HFD load were
caused, at least partially, by SCD1 down-regulation in liver.
Furthermore, PPARc expression was reduced in the liver of
HFD/HFD-LP28 mice. It is known that PPARc is highly
expressed in adipose tissue, but it is also present in many other
types of cells. It has been previously shown that PPARc, which has
wide effects on the lipid metabolism, plays a role in insulin
sensitivity, fatty acid storage in adipocytes, and adipose differen-
tiation [31]. However, liver PPARc regulates triglyceride homeo-
stasis and contributes to hepatic steatosis, accumulating triglycer-
ides in the liver [32]. These results are consistent with our findings,
which show reduced expression of hepatic PPARc parallel with the
prevention of fatty liver in the HFD/HFD-LP28 group. The
combination of the regulation of these genes, CD36, SCD1, and
PPARc, in HFD/HFD-LP28 mice might comprehensively con-
tribute to decreased fat accumulation and enhanced energy
expenditure, followed by body weight loss.
In conclusion, LP28 was demonstrated as a potent anti-obesity
probiotic. The precise mechanisms by which LP28 down-regulates
the expressions of CD36, SCD1, and PPARc remain to be
accurately described and we are currently seeking to find the
answers. However, our results offer evidence that plant-derived
LAB strain, LP28 might be used as a supplement in foods that
could effectively prevent obesity, hepatic steatosis, and metabolic
syndrome.
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